ClinicalTrials.gg
CompletedNCT07553624SB-PIVCUpdated Oct 30, 2026

The Effect of ShotBlocker on Pain, Anxiety, and Satisfaction During Peripheral Intravenous Catheterization

An interventional study of ShotBlocker in Acute Pain and Anxiety, sponsored by Kirsehir Ahi Evran Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Acute Pain with a site in Turkey — 23 open to participants now, 26 under way, none of them phase 3. Acute Pain · Turkey.

Enrollment
43rd of 135
100 · median 80
Started
2026
with 14 others
No phase
130 of 158
19 open now
Registered
148th of 158
by date

Among the 158 studies in Acute Pain with a site in Turkey, this one is the 43rd largest by enrollment of the 135 interventional ones that give a count, is one of 15 that started in 2026, is one of 130 with no phase, and was the 148th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

23 of the 158 studies in Acute Pain with a site in Turkey are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Acute Pain with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the effect of the ShotBlocker device on pain, anxiety, and patient satisfaction during peripheral intravenous catheterization (PIVC). Peripheral intravenous catheterization is a commonly performed procedure in clinical settings and is often associated with pain and anxiety, which may negatively affect patient experience.

The ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying pressure and sensory stimulation at the injection site. Participants will be randomly assigned to either the intervention group, where the ShotBlocker will be used during the procedure, or the control group, where routine care will be provided.Pain will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported , combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10. The findings of this study are expected to contribute to evidence-based nursing practices by providing an effective, low-cost, and non-invasive method for reducing procedural discomfort and improving patient experience during PIVC.

Read the detailed description

Peripheral intravenous catheterization (PIVC) is one of the most frequently performed invasive procedures in clinical practice. Despite its routine nature, it is commonly associated with pain and anxiety, which may negatively influence patient comfort, satisfaction, and overall experience of care. Therefore, effective and practical strategies to reduce procedure-related discomfort are essential in nursing practice.

The ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying mechanical pressure and providing sensory distraction at the injection site. It is inexpensive, easy to use, and does not require additional training or pharmacological intervention, making it suitable for routine clinical use.

This study is designed as a randomized controlled trial to evaluate the effectiveness of the ShotBlocker device during PIVC. Participants will be randomly assigned to either the intervention group, in which the ShotBlocker will be applied during the catheterization procedure, or the control group, in which routine care will be provided without any additional intervention.

Pain intensity will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported by combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10.

All procedures will be performed by trained healthcare professionals following standard clinical protocols. Data will be collected immediately after the procedure. The primary outcome of the study is pain intensity, while secondary outcomes include anxiety and patient satisfaction.

The results of this study are expected to provide evidence for the effectiveness of a simple, non-invasive, and cost-effective method to reduce procedure-related discomfort and improve patient-centered care in clinical settings.

03

Conditions studied

  • Acute Pain
  • Anxiety

Keywords

  • Peripheral Intravenous Catheterization
  • ShotBlocker
  • Pain
  • Anxiety
  • Patient Satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals aged 18 years and older Patients requiring peripheral intravenous catheterization Patients who are conscious and able to communicate Patients who agree to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

Patients with cognitive impairment or inability to communicate Patients with a history of chronic pain or current use of analgesics Patients with dermatological conditions or wounds at the catheterization site Patients who previously experienced peripheral intravenous catheterization within the last 24 hours Patients who refuse to participate in the study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    ShotBlocker Group

    Participants will receive peripheral intravenous catheterization using the ShotBlocker device during the procedure.

    Device: ShotBlocker

  • No intervention
    Control Group

    Participants will receive routine peripheral intravenous catheterization without the use of the ShotBlocker device.

Interventions

  • DeviceShotBlocker

    A non-pharmacological device applied to the skin to reduce pain through mechanical pressure and sensory stimulation during peripheral intravenous catheterization.

06

What researchers measure

Primary outcomes

  1. Pain Intensity During Peripheral Intravenous Catheterization

    Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Immediately after the procedure

Secondary outcomes

  1. Anxiety Level

    Anxiety will be assessed using a visual analog scale with scores ranging from 0 to 10, both before and immediately after the procedure.

    Time frame: Before and immediately after the procedure

  2. Patient Satisfaction

    Patient satisfaction will be assessed immediately after the procedure using a visual analog-based scale supported by , with scores ranging from 0 to 10.

    Time frame: Immediately after the procedure

07

Study locations

1 site
  • Kayseri City Hospital
    Kayseri, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in May 2026, 1 month.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 28, 2026
StartActual
Apr 18, 2026
Primary completionActual
May 29, 2026
CompletionActual
May 29, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Completed
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553624
Collaborators
Kayseri City Hospital
Responsible party
Emine Korkmaz (Assistant Professor, Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Apr 28, 2026
Start date
Apr 18, 2026
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Oct 30, 2026

Study contacts

Emine Korkmaz, PhD
principal investigator · Kirsehir Ahi Evran Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion